Stockscreener 앱 받기
22.70
1.13%
-0.26
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Jim Cramer on Catalyst Pharmaceuticals: “It’s a Very Inexpensive Stock” - Insider Monkey
First Week of September 18th Options Trading For Catalyst Pharmaceuticals (CPRX) - Nasdaq
SG Americas Securities LLC Raises Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Fundamentals with a Technical Breakout Setup - Chartmill
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - sharewise.com
Short Squeeze: What is the next catalyst for Actinium Pharmaceuticals IncProfit Target & Technical Confirmation Trade Alerts - baoquankhu1.vn
Bank Watch: Is Catalyst Pharmaceuticals Inc. stock influenced by commodity pricesJuly 2025 Review & Weekly Momentum Picks - baoquankhu1.vn
Catalyst Pharmaceuticals, Inc. Presents at JP Morgan Healthcare Conference - TradingView — Track All Markets
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Forbes 2026 Small Cap Recognition - Sahm
Will Catalyst Pharmaceuticals Inc. stock see insider buyingQuarterly Trade Summary & Daily Stock Trend Reports - Улправда
How Catalyst Pharmaceuticals Inc. stock benefits from tech adoption2025 Trading Recap & Fast Momentum Stock Entry Tips - Улправда
Does Forbes’ Small-Cap Honor for Sales Growth Reshape the Bull Case For Catalyst Pharmaceuticals (CPRX)? - Yahoo Finance
Is Catalyst Pharmaceuticals (CPRX) Still Attractive After Recent Share Price Pause? - Yahoo Finance
How Forbes’ Small-Cap Accolade Will Impact Catalyst Pharmaceuticals (CPRX) Investors - Sahm
Will Catalyst Pharmaceuticals Inc. stock benefit from green energy trendsEntry Point & Consistent Profit Trading Strategies - Улправда
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? - AOL.com
How Catalyst Pharmaceuticals Inc. stock performs in rising dollar environmentTrade Exit Report & Verified Chart Pattern Trade Signals - ulpravda.ru
Funds from operations of Catalyst Pharmaceuticals, Inc. – FWB:CN2 - TradingView — Track All Markets
Is Catalyst Pharmaceuticals Inc. stock a buy before product launchesJuly 2025 Market Mood & Real-Time Market Trend Scan - ulpravda.ru
Will Catalyst Pharmaceuticals Inc. stock maintain dividend yield2025 Geopolitical Influence & Free Community Consensus Stock Picks - Улправда
Santhera Seals APAC Pact For Agamree - Citeline News & Insights
Is Catalyst Pharmaceuticals (CPRX) Stock Undervalued Right Now? - Yahoo Finance
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies - The Manila Times
Catalyst Pharmaceuticals Receives Prestigious Ranking on - GlobeNewswire
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Prospects Need A Boost To Lift Shares - 富途牛牛
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Cross Above 200-Day Moving AverageHere's Why - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) - The Manila Times
How 12 Notre Dame students will spend a week inside rare disease care - Stock Titan
Aug PreEarnings: Is Catalyst Pharmaceuticals Inc CN2 stock a contrarian opportunityJuly 2025 Retail & Weekly High Return Forecasts - moha.gov.vn
Why Catalyst Pharmaceutical (CPRX) is a top value stock for the long term - MSN
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? - The Motley Fool
Aug Closing: Why Catalyst Pharmaceuticals Inc stock remains resilient2025 Earnings Surprises & AI Powered Market Entry Strategies - moha.gov.vn
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade - ts2.tech
Exchange Traded Concepts LLC Grows Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Analysts see big upside in Catalyst Pharmaceuticals, Inc. (CPRX) - MSN
Voya Investment Management LLC Has $8.79 Million Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Texas Permanent School Fund Corp Boosts Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Wedge Capital Management L L P NC Makes New $2.86 Million Investment in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
Catalyst Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains - 富途牛牛
First Week of February 2026 Options Trading For Catalyst Pharmaceuticals (CPRX) - Nasdaq
Toth Financial Advisory Corp Has $42,000 Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Market Fear: Can Catalyst Pharmaceuticals Inc. stock outperform in 2025 bull marketPortfolio Return Summary & AI Powered Market Entry Ideas - Улправда
Market Fear: Will Catalyst Pharmaceuticals Inc CN2 stock sustain bullish trend into 2025Quarterly Profit Review & Consistent Growth Stock Picks - moha.gov.vn
Can Catalyst Pharmaceuticals Inc. stock outperform in 2025 bull marketJuly 2025 Price Swings & Daily Momentum Trading Reports - Улправда
If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now - MSN
Why Catalyst Pharmaceuticals Inc. stock remains resilientQuarterly Market Summary & Safe Entry Momentum Stock Tips - DonanımHaber
What hedge fund moves indicate for Catalyst Pharmaceuticals Inc. (CN2) stock2025 Technical Patterns & Growth Focused Entry Reports - DonanımHaber
Assessing Catalyst Pharma After 600% Surge and Rare Disease Expansion in 2025 - Yahoo Finance
How A New US$200 Million Buyback At Catalyst Pharmaceuticals (CPRX) Has Changed Its Investment Story - Yahoo Finance
Molly Harper Takes Money Off The Table, Sells $621K In Catalyst Pharmaceuticals Stock - Benzinga
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
4.73%
0.92%
자본화:
|
볼륨(24시간):